Article

Cymbalta for Chronic Pain

As reported by the Wall Street Journal, the FDA is seeking advice from a panel of medical experts on whether the antidepressant Cymbalta should be used as a treatment for chronic pain.

As reported by the Wall Street Journal, the FDA is seeking advice from a panel of medical experts on whether the antidepressant Cymbalta should be used as a treatment for chronic pain.

Eli Lilly & Co, the company that markets the drug, is seeking approval for the expanded use as a treatment for chronic pain conditions that would include pain caused by osteoarthritis or low back pain. Currently, the drug is also approved to treat diabetic nerve pain, fibromyalgia, and anxiety.

However, there are safety concerns associated with the drug, including possible liver damage and bleeding risks. The drug will be reviewed Thursday.

Related Videos
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
© 2024 MJH Life Sciences

All rights reserved.